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Objective: This review aims to summarize the current literature on patient-reported outcomes 
(PROs) in spondyloarthritis (SpA).
Patients and methods: We performed a systematic literature review to identify studies (origi-
nal articles and narrative and systematic reviews) regarding PROs (health-related quality of life 
[HRQoL], satisfaction, preferences, adherence/compliance, and persistence) in SpA patients 
published in the European Union through December 2016. International databases (Medline/
PubMed, Cochrane Library, ISI Web of Knowledge, Scopus) were searched using keywords 
in English. The methodological quality of the studies was assessed using the Oxford Centre for 
Evidence-Based Medicine criteria.
Results: A total of 26 publications met the inclusion criteria. Generally, studies indicated 
that SpA has a negative impact on patients’ HRQoL. In patients with ankylosing spondylitis, 
physical domains were more affected than emotional ones, whereas for psoriatic arthritis, both 
physical and psychological factors were strongly affected by the disease. Data indicated that 
biological agents (BAs) greatly contributed to improvement in HRQoL in both ankylosing 
spondylitis and psoriatic arthritis patients. Findings on compliance with BAs were heteroge-
neous. However, persistence rates exceeded 50% irrespective of the BA administered. Results 
on preferences indicated that most SpA patients prefer being involved in decisions regarding 
their treatment and that besides efficacy and safety, frequency and route of administration may 
influence patients’ preferences for BAs.
Conclusion: Implementing management programs for SpA patients focuses on the physical, 
emotional, and social consequences of the disease, in addition to assessing and including patient 
preferences in the treatment decision-making process, could be crucial to improve patients’ 
HRQoL and ensure their satisfaction and compliance with treatment.
Keywords: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, patient-reported 
outcomes, European Union, systematic review
Introduction
Spondyloarthritis (SpA) refers to a group of interrelated inflammatory diseases that 
share some features, including articular and extra-articular manifestations.1 SpA affects 
1%–3% of the general population. In European countries, the reported prevalence varies 
between 0.3% and 1.9%.2 Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are 
the most frequent types of SpA. AS mainly affects the spine and sacroiliac joint and to 
a lesser extent the peripheral joints and entheses. PsA is characterized by the involve-
ment of both peripheral and/or spinal joints and skin manifestations.2,3 The European 
prevalence of AS is 0.03%–1.8%, while prevalence is 0.05%–0.42% for PsA.4
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PsA causes joint damage that leads to loss of articular 
function; specifically, a high percentage of PsA patients have 
more than one deformed joint and about 20% develop a very 
destructive disabling form of arthritis.5 As a consequence, 
progression of PsA leads to a reduction in patients’ functional 
capacity, affecting their social and working lives.6 Various 
studies have suggested that SpA has a negative impact on 
functional status and patients’ health-related quality of life 
(HRQoL),7–9 and it is associated with an increased risk 
of death.5
AS patients typically present axial skeleton and sacro-
iliac joint involvement, resulting in structural and functional 
impairment. Additionally, many extra-articular features may 
also occur in AS patients, including uveitis, osteoporosis, 
bowel disease, and cardiac, pulmonary, skin (psoriasis), and 
kidney involvement.10 The incidence of cardiovascular disease 
and mortality is also increased in AS patients.5 Adults with 
AS may thus have significantly reduced HRQoL, in addition 
to limitations in physical functioning and comorbidities that 
are strongly associated with decreased work productivity.7
In view of the clinical and social implications of SpA, 
management of SpA patients should aim to prevent struc-
tural damage and preserve their functional status, in order to 
optimize HRQoL.11–13 With this aim, new therapies, such as 
biological therapies, have been developed, and new treatment 
strategies, eg, treat to target, have been adopted over the last 
decade.14 The implementation in routine-practice of biological 
agent (BA) therapy11–13 has led to a significant improvement 
in clinical outcomes, including the physical functioning of 
patients with rheumatic disease.15 However, poor adherence 
to medication in SpA patients remains a challenge in clinical 
practice.16 New BAs involve different routes of administra-
tion and different toxicity, and are sometimes associated 
with higher drug costs, all of which may influence patient 
adherence and preference for medication.17 In view of the 
new scenario, a more patient-centered approach to decision 
making is needed. In fact, assessing and including patients’ 
preferences within routine clinical practice are related to an 
increase in medication adherence, as well as improved treat-
ment outcomes. This work reviews and summarizes the cur-
rent literature on patient-reported outcomes (PROs) in patients 
with SpA (AS and PsA) in the European Union (EU).
Methods
We performed a systematic literature review to identify studies 
on PROs in SpA (AS and PsA) patients. Studies assessing 
HRQoL, satisfaction, adherence/compliance, or persistence 
with treatment and patients’ preferences for treatment in SpA 
populations published in the EU through December 2016 
were selected. As recommended by the Cochrane Handbook 
for Systematic Reviews of Interventions,18 publicly acces-
sible international databases (Medline/PubMed, Cochrane 
Library, ISI Web of Knowledge, Scopus) were searched 
using keywords in English joined by the Boolean operators 
“OR” and “AND” (Table 1).
inclusion criteria
We included original articles, narrative reviews, and sys-
tematic reviews in English and Spanish that evaluated PROs 
(HRQoL, satisfaction, adherence/compliance, or persistence 
with treatment and patients’ preferences) in SpA patients in 
EU setting.
exclusion criteria
We excluded studies conducted in non-EU countries, letters 
to the editor, editorials, experts’ opinions, case studies, 
congress proceedings, mixed-population studies, those that 
focused on only one explanatory factor, and studies related 
to specific medical interventions.
Selection of studies
Following removal of duplicates and irrelevant publications, 
two independent researchers screened the remaining studies 
based on preset inclusion and exclusion criteria. Discrep-
ancies were resolved by consensus. The methodological 
Table 1 Search terms and search strategies
Number of  
search terms
Search terms
1 Ankylosing spondylitis (MeSH)
2 Ankylosing spondylitis
3 Psoriatic arthritis (MeSH)
4 Psoriatic arthritis
5 Quality of life (MeSH)
6 QoL
7 Health related quality of life
8 HRQoL
9 Medication adherence (MeSH)
10 Patient compliance (MeSH)
11 Medication persistence (MeSH)
12 Adherence
13 Compliance
14 Persistence
15 Satisfaction
16 Preference
17 Utility
18 Utilities
Search strategies
(1 OR 2) AND (5 OR 6 OR 7 OR 8)
(3 OR 4) AND (5 OR 6 OR 7 OR 8)
(1 OR 2) AND (9 OR 10 OR 11 OR 12 OR 
13 OR 14 OR 15 OR 16 OR 17 OR 18)
(3 OR 4) AND (9 OR 10 OR 11 OR 12 OR 
13 OR 14 OR 15 OR 16 OR 17 OR 18)
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quality of the studies was assessed using Oxford Centre for 
Evidence-Based Medicine criteria.19
Results
Studies selected
The database searches yielded a total of 8,954 titles. Of these, 
8,864 were excluded as irrelevant to study purposes (4,748, 
53%) or duplicates (3,916, 43.7%). Following full-text read-
ing and application of the inclusion/exclusion criteria, 26 of 
the remaining 290 publications were included in the review 
(Figure 1). Most publications reviewed (n=16, 61.5%) were 
cross-sectional studies examining HRQoL in SpA patients, 
while a lower proportion evaluated other PROs such as per-
sistence, satisfaction, or preferences (Table 2).
HRQoL in SpA patients
Of the 18 publications examining HRQoL in SpA patients, 
13 (72.5%) employed generic HRQoL instruments, while 
only four used disease-specific questionnaires, alone or in 
combination with generic ones (Tables 2 and 3).
HRQoL in SpA patients compared with other 
rheumatological disorders and the general 
population
Salaffi et al20 revealed that inflammatory rheumatic diseases, 
including SpA, have a negative impact on patients’ HRQoL, 
affecting both physical (physical component summary [PCS]) 
and mental (mental component summary [MCS]) dimensions. 
PCS was more affected in AS, whereas both physical and 
emotional well-being deteriorated in patients with PsA.
Correlation between clinical variables and HRQoL 
in SpA
Of the studies selected, two20,21 sought to identify explanatory 
clinical factors for HRQoL in SpA. In particular, Salaffi 
et al20 showed that for inflammatory rheumatic diseases, 
high disease-activity score, chronic comorbidity, and radio-
graphic damage negatively affected PCS, while the severity 
of psoriatic lesions (Psoriasis Area and Severity Index) was 
significantly associated with poor MCS in PsA patients. 
In the same line, Jajić et al21 observed that for AS patients, 
clinical variables correlated mainly with PCS, whereas in PsA 
patients both PCS and MCS were affected by the disease. 
Functional status, measured by the Bath Ankylosing Spon-
dylitis Functional Index (BASFI), had the strongest impact 
on PCS in both diseases.
Depression, anxiety, and HRQoL in SpA
Kotsis et al22 and Hyphantis et al23 investigated the preva-
lence of major depressive disorders in SpA and rheumatoid 
arthritis (RA) and their association with HRQoL. Both studies 
showed that psychological factors were strongly associated 
with HRQoL in PsA patients. In particular, both anxiety and 
concern about bodily symptoms were independent correlates 
of the physical domain of HRQoL.22 On the other hand, only 
cognitive variables were important correlates of HRQoL in 
AS patients, with illness concern being the only significant 
independent correlate of physical HRQoL.23
HRQoL and work productivity in SpA patients
Two studies evaluated the relationship between HRQoL 
and productivity loss in SpA patients. Chorus et al24 showed 
a positive association between work and HRQoL PCS; 
however, no association was found with MCS. Kawalec 
et al25 observed that patients’ HRQoL, expressed as utility 
scores, was negatively correlated with absenteeism, presen-
teeism, and indirect costs, suggesting that higher HRQoL was 
associated with higher productivity and lower indirect costs. 
Disease-activity score was positively correlated with indirect 
costs and negatively correlated with HRQoL. Therefore, 
the greater the disease activity, the lower the utility and the 
larger the indirect cost.
Compliance and HRQoL in SpA patients
Hromadkova et al26 assessed the relationship between drug 
compliance and HRQoL in patients with different rheumatic 
Figure 1 Flowchart of study selection according to PRiSMA.
Abbreviation: PRiSMA, Preferred Reporting items for Systematic Reviews and 
Meta-Analyses.
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disorders, including SpA. A significantly negative correlation 
between compliance and HRQoL PCS was found in SpA 
patients, suggesting that patients with worse HRQoL might 
be more compliant with treatment.
Influence of biological therapies on SpA-patient 
HRQoL
Three of the studies investigated the impact of BAs on 
HRQoL in SpA patients in the clinical practice setting. Saad 
et al27 reported a significant improvement in all Short Form 
(SF)-36 subscales after 6 months of therapy with BAs, with 
greatest improvements observed in PCS. Sieper et al28 found 
that in nonradiographic axial SpA (nr-axSpA) patients, 
treatment with BAs was associated with improved clinical 
outcomes (pain, remission, acute episodes) compared to 
BA-naïve patients. Furthermore, BA-naïve patients reported 
greater presenteeism, overall work impairment, and activity 
impairment than BA-treated patients. In line with previous 
studies, Wallman et al29 showed that following BA treat-
ment, both HRQoL (EuroQoL 5D utility and visual analog 
scale) and clinical outcomes (pain, erythrocyte-sedimentation 
rate and CRP) improved rapidly in both nr-axSpA and 
AS patients.
HRQoL in AS patients
Factors influencing HRQoL in AS patients
Kucharz et al30 observed that almost two-thirds of AS patients 
considered pain a very important risk factor in their HRQoL. 
Table 2 Description of studies reviewed
Design Evidence 
level
PROs 
evaluated
PROMs used
Salaffi et al20 (italy) Cross-sectional 2C HRQoL SF36
Jajić et al21 (Croatia) Cross-sectional 2C HRQoL SF36
Kotsis et al22 (Greece) Cross-sectional 2C HRQoL wHOQoL-Bref
Hyphantis et al23 (Greece) Cross-sectional 2C HRQoL wHOQoL-Bref
Chorus et al24 (the Netherlands) Cross-sectional 2C HRQoL SF36
Kawalec et al25 (Poland) Cross-sectional 2C HRQoL eQ5D
Saad et al27 (UK) Prospective study  
(6-month follow-up)
2B HRQoL Ad hoc questionnaire
Sieper et al28 (Germany, 
France, Spain, italy, UK)
Cross-sectional 2C HRQoL SF36
eQ5D
Kucharz et al30 (Poland) Cross-sectional 2C HRQoL SF36
Ariza-Ariza et al31 (Spain) Cross-sectional 2C HRQoL eQ5D
de las Peñas et al32 (Spain) Cross-sectional 2C HRQoL ASQoL
Ariza-Ariza et al33 (Spain) Cross-sectional 2C HRQoL eQ5D
O’Dwyer et al34 (ireland) Cross-sectional 2C HRQoL PsAiD12
DLQi
eQ5D
SF36
Tälli et al35 (multicenter – 
13 countries)
Cross-sectional 2C HRQoL PsAiD12
Puyraimond-Zemmour et al36 
(multicenter – 13 countries)
Cross-sectional 2C HRQoL eQ5D
PsAQoL
Brodszky et al37 (Hungary) Cross-sectional 2C HRQoL SF36
Hromadkova et al26 
(Czech Republic)
Cross-sectional 2C HRQoL
Compliance
SF36
CQR
wallman et al29 (Sweden) Prospective (3-year follow-up) 1C HRQoL
Persistence
eQ5D
Kaplan–Meier curves
López-González et al39 (Spain) Systematic literature review 2A Compliance
Persistence
Lyu et al40 (Germany) Retrospective (12-month follow-up) 2B Persistence Kaplan–Meier curves
Saad et al41 (UK) Prospective (3-year follow-up) 1B Persistence Kaplan–Meier curves
Kristensen et al42 (Sweden) Prospective (2-year follow-up) 1B Persistence Kaplan–Meier curves
Favalli et al43 (italy) Retrospective (8-year follow-up) 2B Persistence Kaplan–Meier curves
Renzi et al44 (italy) Cross-sectional 2C Satisfaction Ad hoc questionnaire
Nolla et al45 (Spain) Cross-sectional 2C Preferences Rank-based conjoint analysis
Rothery et al46 (UK) Cross-sectional 2C Preferences DCe
Abbreviations: ASQoL, Ankylosing Spondylitis Quality of Life; CQR, Compliance Questionnaire Rheumatology; DCe, discrete-choice experiment; DLQi, Dermatology 
Life Quality index; eQ, euroQol; HRQoL, Health-Related Quality of Life; PsAiD, Psoriatic Arthritis impact of Disease; SF, Short Form; wHOQoL-Bref, world Health 
Organization Quality of Life – brief.
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Table 3 Characteristics of HRQoL-related studies reviewed
Objective Demographic and clinical 
characteristics
Main results
Salaffi et al20 
(italy)
To compare HRQoL scores 
among patients with RA, 
PsA, and AS and a selected 
sample of healthy people and 
determine their relationship 
with measures of clinical 
condition
RA (n=469, 71.8% female, mean age 
57.5 [SD 14.3] years, disease duration 
6.1 [SD 4.2] years)
AS (n=164, 18.9% female, mean age 
51.7 [SD 9.2] years, disease duration 
8.2 [SD 4.6] years)
Axial PsA (n=65, 50.7% female, mean 
age 58.2 [SD 10.3] years, disease 
duration 8.4 [SD 4.3] years)
Peripheral PsA (n=101, 61.4% female, 
mean age 60.7 [SD 11.6] years, disease 
duration 7.5 [5.3] years)
General population (n=1,579, 50.2% 
female, mean age 55.2 [SD 19.2] years)
Compared to healthy controls, both components of the 
SF36 questionnaire (PCS and MCS) were significantly 
impaired in patients with the three inflammatory 
diseases (P,0.0001). Compared to other rheumatoid 
diseases, MCS were lower in PsA patients.
The PCS was influenced by high disease activity (DAS, 
P,0.0001), chronic comorbidity (P,0.0001), and 
radiographic damage (P=0.004) in all diseases.
An association was found in AS (P.0.001) and axial 
PsA (P=0.009) with low educational level and MCS. 
in peripheral PsA (P,0.0001) and axial PsA (P=0.03), 
severity of psoriatic lesions was associated with 
poor MCS.
Jajić et al21 
(Croatia)
To assess clinical 
variables with the best 
correlation with HRQoL 
in patients with SpA
AS (n=32, 62.5% female, mean age 
51.4 [SD 9.7] years, disease duration 
7 [2–11] years)
PsA (n=22, 50% female, mean age 54.2 
[SD 8.3] years, disease duration 10.5 
[4–12] years)
Although perception of general health was similar in 
both groups,  AS patients had reduced HRQoL values 
for physical domains, whereas PsA patients presented 
reduced HRQoL values for both PCS and MCS.
For AS patients, clinical variables correlated mainly with 
the PCS, while in PsA patients correlations between 
clinical variables and SF36 were more distributed.
in both diseases, BASFi had the strongest correlation 
with PCS.
Kotsis et al22 
(Greece)
To compare psychological 
distress in PsA and RA and 
test whether the association 
between psychological 
variables and HRQoL was 
similar in the two forms of 
arthritis
PsA (n=83, 47% female, mean age 
48.9 [SD 12.4] years, disease duration 
9.2 [SD 6] years)
RA (n=199, 82.4% female, mean age 
55.2 [SD 12.7] years, disease duration 
13.7 [SD 10.5] years)
The prevalence of moderate and severe levels of 
depressive symptoms (PHQ 9$10) was similar in PsA 
(21.7%) and RA (25.1%) patients.
Among PsA patients, depression symptoms were more 
frequent in those with polyarthritis (36.7%) compared 
to those with oligoarthritis (9.8%) and spondyloarthritis 
(16.7%).
in general, all participants perceived their arthritis as a 
chronic disease that could not be controlled.
According to a regression analysis, both anxiety 
(β=-0.28) and concern about bodily symptoms 
(β=-0.33) were independent correlates of the physical 
domain of HRQoL in PsA patients.
Hyphantis et al23 
(Greece)
To compare psychological 
distress symptoms and 
illness perceptions in AS and 
RA and test whether their 
association with HRQoL 
was similar
AS (n=55, 14.5% female, mean age 
42.9 [SD 10.9] years, disease duration 
15.3 [SD 11.5] years)
RA (n=199, 82.4% female, mean age 
55.2 [SD 13.6] years, disease duration 
13.7 [SD 11.5] years)
The prevalence of clinically significant depressive 
symptoms (PHQ 9$10) was lower in AS (14.8%) 
compared to RA (25.1%) patients (P=0.09), but 
psychological distress levels and HRQoL were similar in 
both disorders.
illness concern (β=-0.37) was the only significant 
independent correlate of physical HRQoL in AS. 
Symptoms of anxiety and depression had a minor 
contribution to physical HRQoL.
Chorus et al24 
(the Netherlands)
To investigate the 
relationship between work 
and HRQoL in patients with 
RA and AS aged 16–59 years
AS (n=658, 29.9% female, mean age 
43.5 [SD 9.4] years, disease duration 
12.3 [SD 8] years)
RA (n=1,056, 72.3% female, mean age 
49 [SD 8.3] years, disease duration 
11.9 [SD 9.1] years)
PCS was worse in patients with RA than AS, although 
MCS was reported to be more favorable in RA 
than AS.
A positive association between work and PCS in 
both group of patients was assessed. However, no 
association between work and MCS was fond. 
Kawalec et al25 
(Poland)
To investigate associations 
among activity, utility of 
PsA-affected patients, and 
productivity loss
PsA (n=50, 58% female, mean age 45.5 
[35.75–53.5] years, age at onset 36.5 
[29–44] years)
PsA has been demonstrated to reduce patients’ HRQoL 
and generate considerable indirect costs, mainly due to 
lower productivity at work.
(Continued)
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Table 3 (Continued)
Objective Demographic and clinical 
characteristics
Main results
Patients’ HRQoL, expressed as utility, was correlated 
with absenteeism (-0.537, P=0.002) and presenteeism 
(-0.682, P,0.001). Utility showed a significantly 
negative moderate–strong correlation with absenteeism, 
presenteeism, and total indirect cost (-0.772, P,0.001).
Disease activity was significantly correlated with indirect 
cost (absenteeism 0.618, presenteeism 0.838, total cost 
0.864, P,0.0001) and HRQoL (-0.878, P,0.0001).
Hromadkova 
et al26 (Czech 
Republic)
To elucidate the relationship 
between drug compliance 
and HRQoL in patients 
with different rheumatic 
disorders
SpA (n=41, 68.1% female, mean age 
50 [22–79] years, disease duration 
3.8 [0.7–8.3] years)
RA (n=178, 78.7% female, mean age 
59 [26–82] years, disease duration 
7.4 [0.5–19.9] years)
SSc (n=41, 75.6% female, mean age 
58 [26–80] years, disease duration 
6.8 [0.5–23.9] years)
JiA (n=23, 73.9% female, mean age 
28 [18–51] years, disease duration 
6.8 [0.6–20.9] years)
A significantly negative correlation between 
compliance and PCS was established in SpA patients 
(-0.301, P,0.05).
Saad et al27 (UK) To evaluate the impact of 
BAs on HRQoL, functional 
status in PsA patients, and 
study-potential predictors 
for HRQoL
PsA (n=596, 52.3% female, mean age 
45.7 [SD 11.1] years, disease duration 
12.4 [SD 8.7] years)
The largest changes were achieved within the first 
6 months of BA treatment, and were sustained 
throughout the follow-up period (18 months).
At 6 months, improvement for PCS was 53.2% (95% 
Ci 44.5%–61.9%), whereas for the mental component 
scale it was 16.9% (95% Ci 14.7%–19.2%). There 
was a statistically significant association between 
improvement in PCS and change in DAS28 (β=2.92 per 
unit improvement, 95% Ci 2.10–3.75).
Sieper et al28 
(Germany, 
France, Spain, 
italy, UK)
To assess the impact of 
nr-axSpA on patients and 
society based on real-world 
evidence from the Adelphi 
Disease Specific Programme
axSpA (n=631, 29.6% female, mean age 
41.8 [SD 12] years, disease duration 
51.6 [SD 60] months, cDMARD, 
25.58%, BAs 36.1%, 66.5% responders 
to treatment, 24.8% nonresponders)
eQ5D utility scores were lower in patients with 
nr-axSpA versus general population-matched 
controls (0.776 vs 0.884, P,0.001).
Pain-score reduction was higher in BA-treated than 
BA-naïve (2.5 vs 4.0, P,0.001) patients.
BA-treated patients were more likely to be in remission 
than BA-naïve patients (67% vs 34%, P,0.001).
BAs-naïve patients reported greater presenteeism 
(28% vs 16%, P=0.037), overall work impairment (37% 
vs 19%, P=0.018), and activity impairment (31% vs 23%, 
P=0.045) than BA-treated patients. 
wallman et al29 
(Sweden)
To compare clinical 
development, HRQoL, 
and treatment adherence 
between nr-axSpA and AS 
patients during 3 years of 
BA in clinical practice
nr-axSpA (n=86, 38% female, mean 
age 38 [SD 13] years, disease duration 
9 [SD 9] years)
AS (n=238, 24% female, mean age 
43 [SD 12] years, disease duration 
16 [SD 12] years)
Following BA initiation, mean vAS global, vAS 
pain, eQ5D utility, evaluator’s global, eSR, and 
CRP improved rapidly in both groups, and within 
3–6 months had reached a plateau, which was then 
sustained for 3 years.
Kucharz et al30 
(Poland)
To obtain patients’ opinions 
on factors associated with 
AS that may potentially 
influence their HRQoL
AS (n=53, 22.2% female) Patients considered pain (64% [0, not important at all 
to 4, very important], mean score 3.5), to need help of 
another person for everyday functioning (52%, 3.4) and 
impairment in family life (49%, 3.4) very important risk 
factors in their HRQoL.
Management of AS, including treatment (23%, 2.5) and 
frequent hospitalizations (7.5%, 2.4), were not considered 
a significant factor impairing patients’ HRQoL.
Young male patients were more worried by risk of losing 
of their jobs, while an impairment of sexual life due to 
AS was more important to male than to female patients.
(Continued)
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Table 3 (Continued)
Objective Demographic and clinical 
characteristics
Main results
Ariza-Ariza et al31 
(Spain)
To determine physical 
function and HRQoL of 
Spanish patients with AS
AS (n=92, 25% female, mean age 
40.7 [SD 9.1] years, disease duration 
11 [SD 7.8] years)
BASFi had a good correlation (Pearson .0.6) with 
PCS (r=0.75, R2=0.56; P,0.0001), patient and physician 
global assessment, pain measurements, BASDAi, and 
most HRQoL scores.
Physician global assessment (P=0.043), patient paint 
assessment (P=0.036), and BASFi score (P=0.002) were 
independently associated with the SF36.
Only BASFi score showed an independent association 
with the EQ5D health profile (P=0.002).
de las Peñas 
et al32 (Spain)
To assess correlations 
among mobility, function, 
and HRQoL in subjects 
with AS
AS (n=42, 20% female, mean age 
46 [SD 9] years, disease duration 
15 [SD 3] years)
All domains of HRQoL except mental health were 
negatively correlated with BASFi score (r=-0.35 
to -0.75, P,0.05).
Physical function, bodily pain, general health, vitality, 
and social role were negatively correlated with BASDAi 
score (r=-0.35 to –0.63, P,0.05).
Few mobility measures of BASMi showed a positive 
correlation with SF36 domains: lumbar flexion 
(modified Schober) correlated with physical function 
(r=0.36, P=0.03), and maximal intermalleolar distance 
correlated with physical function (r=0.36, P=0.034) and 
social role (rs=0.33, P=0.04).
Ariza-Ariza et al33 
(Spain)
To identify variables 
associated with utility of 
health states in patients 
with AS
AS (n=70, 24.7% female, mean age 
43.7 [SD 9.1] years, disease duration 
10.8 [SD 8.1] years)
in the univariate analysis, patient global assessment 
(r=-0.66, P,0.0001), BASDAi (r=-0.68, P,0.0001), and 
BASFi (r=-0.75, P,0.0001) had good correlations with 
eQ5D values.
in the multivariate analysis, BASFi (β=-0.0679, P=0) and 
BASDAi (β=-0.0441, P=0.004) kept an independent 
association with utility.
O’Dwyer et al34 
(ireland)
To assess health-related 
physical fitness of adults 
with AS, compare this to 
the general population, and 
examine the relationship 
between physical fitness and 
condition-specific outcomes
AS (n=39, 18% female, mean age 
40 [SD 9] years, disease duration 
6 [SD 10] years)
Compared to age- and sex-matched population 
controls, AS patients showed significantly lower 
cardiorespiratory fitness, flexibility, muscular strength 
and endurance, and increased body fat.
Physical fitness was associated with physical function 
(BASFi). Flexibility (BASMi) had the largest contribution 
of any individual physical fitness component, and 
accounted for 35.9% of the total variance in BASFi 
score (β=-0.599, P=0.038).
Aerobic capacity was associated with HRQoL, 
accounting for 11.2% of the variance (β=-0.334, 
P,0.001).
Disease activity was not associated with any physical 
fitness component.
Tälli et al35 
(multicenter)
To explore the meaning of 
PGA in PsA by examining 
associations with domains 
of health assessed by the 
PsAiD
PsA (n=223, 51.1% female, mean age 
51 [SD1 3.3] years, disease duration 
9.9 [SD 10.1] years)
Physical domains of PsAiD – pain (0.72, P,0.0001), 
discomfort (0.73, P,0.0001), work and/or leisure 
activities (0.70, P,0.0001), and functional capacity 
(0.68, P,0.0001) – had stronger correlation with 
patients’ assessment (PGA) than other PROs or 
physician-based assessments, such as HAD (0.59, 
P,0.0001) and SF36 PCS (-0.56, P,0.0001).
A good correlation was established between PGA and 
psychological and social impact of PsAiD: coping (0.77, 
P,0.0001), anxiety (0.68, P,0.0001), fatigue (0.66, 
P,0.0001), depression (0.65, P,0.0001), and social 
participation (0.58, P,0.0001). A moderate or low 
correlation was found between PGA and impact related 
to skin (0.34–0.47, P,0.0001). Joint counts were poorly 
correlated with PGA (0.24–0.52, P,0.0001).
(Continued)
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Table 3 (Continued)
Objective Demographic and clinical 
characteristics
Main results
PGA assessment was explained by coping (β=0.287), 
pain (β=0.540), work and/or leisure activities (β=0.141), 
and anxiety (β=0.109).
Puyraimond-
Zemmour et al36 
(multicenter)
To explore the link between 
PASS and patient-perceived 
impact in RA and PsA
PsA (n=446, 50.6% female, mean age 
50.6 [SD 12.6] years, disease duration 
9.6 [SD 9.5] years)
RA (n=531, 78.5% female, mean age 
55.8 [SD 13.3] years, disease duration 
12.6 [SD 10.3] years)
Multivariate analyses of the five domains of 
PsAiD – pain, functional capacity, fatigue, sleep 
disturbance, and coping – indicated that in PsA patients, 
pain (OR 0.63, 95% Ci 0.52–0.75) and coping (OR 
0.63, 95% Ci 052–0.75) were associated in PASS after 
adjustment on DAS28 (OR 0.83, 95% Ci 0.71–0.97).
Brodszky et al37 
(Hungary)
To compare PsAQoL, HAQ, 
and eQ5D in terms of ability 
to assess disease severity 
in PsA
PsA (n=183, 57% female, mean age 
51.1 [SD 12.9] years, disease duration 
9.2 [SD 9.2] years)
eQ5D and PsAQoL scores were strongly correlated 
with clinical variables, such as HAD (-0.71 to 0.64, 
P,0.05), BASDAi (-0.69 to 0.62, P,0.05), PGA (-0.63 
to 0.52, P,0.05), and patient pain vAS (-0.68 to 0.54, 
P,0.05).
Disease duration (-0.14 to 0.15, P,0.05) and psoriasis 
(-0.13 to 0.12, not significant) correlated weakly with 
HRQoL instruments.
Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; BAs, biological agents; BASDAi, Bath Ankylosing Spondylitis Disease Activity index; BASFi, BAS 
Functional index; BASMi, BAS Metrology index; DAS, disease-activity score; eQ, euroQol; eSR, erythrocyte-sedimentation rate; HAQ; Health Assessment Questionnaire; HRQoL, 
health-related quality of life; MCS, mental component summary; nr, nonradiographic; PASS, patient-acceptable symptom state; PCS, physical component summary; PGA, patient 
global assessment; PHQ 9, Patient Health Questionnaire; PsA, psoriatic arthritis; PsAiD, Psoriatic Arthritis impact of Disease; SF, Short Form; vAS, visual analog scale.
In addition, around 50% of patients indicated that the need for 
assistance in activities of daily living (ADL) and impairment 
in family life potentially influenced their HRQoL. Young 
male patients were more concerned by the risk of losing their 
jobs than older ones, while impairment of sexual life due to 
the disease was more important to males than to females. 
Management of the disease (treatment or frequent hospital-
ization) was not considered a significant factor impairing 
their HRQoL.
Patient-reported measures and HRQoL in AS patients
Mobility and physical function are the most important 
end points for AS patients, and several instruments have 
been developed to evaluate disease activity from patient 
perspectives (BAS Disease Activity Index [BASDAI]) 
and physical functioning (BASFI and BAS Metrology 
Index). A correlation between physical function (BASFI) 
and HRQoL in AS patients was established by Ariza-Ariza 
et al,31 showing that BASFI score presented an independent 
association with HRQoL. This association was confirmed 
by de las Peñas et al.32 These authors observed that function 
(BASFI) and disease activity (BASDAI) were correlated 
with HRQoL (physical function, pain, and vitality domains). 
In the same vein, Ariza-Ariza et al33 found that physical 
function (BASFI) and disease activity (BASDAI) were 
the main determinants of health-state utility values in AS 
patients. Finally, a recent study published by O’Dwyer et al34 
confirmed that adults with AS show a significant reduction in 
physical fitness compared to age- and sex-matched healthy 
controls. The AS group demonstrated significantly lower 
cardiorespiratory fitness, flexibility, muscular strength, and 
increased body fat compared to controls. All components 
of physical fitness were associated with physical function 
(BASFI), while only aerobic capacity was associated with 
HRQoL (ASQoL).
HRQoL in PsA patients
Patient-reported measures and HRQoL in 
PsA patients
Tälli et al35 showed that patient global assessment (PGA) in 
PsA was determined mainly by physical but also physiological 
aspects of the disease. In particular, coping, pain, work, 
leisure activities, and anxiety were identified as the main 
explanatory factors for PGA scores. Skin lesions seemed to 
have a lower impact on PGA than joint involvement, which 
had a larger effect on PsA patients’ HRQoL. Similarly, 
Puyraimond-Zemmour et al36 established an association 
between pain and coping with patient-acceptable symptom 
state, showing that less pain and better coping were correlated 
with better level of acceptability of disease status.
Disease severity and HRQoL in PsA patients
Brodsky et al37 found strong correlations between both generic 
(EuroQol 5D) and specific HRQoL (PsAQoL) instruments 
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and disease severity assessed by Health Assessment Question-
naire (HAQ) disability score, patient-pain visual analog scale, 
PGA, and BASDAI. However, disease duration and pso-
riasis correlated weakly with these HRQoL instruments.
Compliance and persistence in 
SpA patients
According to the definition of adherence/compliance (extent 
to which patient acts in accordance the prescribed interval 
and dose of dosing regimen) and persistence (duration of time 
from initiation to discontinuation of therapy),38 five studies 
evaluated persistence to BA therapy in SpA patients, one 
assessed compliance with BA treatment, while the remaining 
publication was a systematic review (Table 4).
The systematic review39 reported great variability in 
the operational definition and measurement of adherence/
compliance among studies. Most studies focused on persis-
tence, measured by survival time, retention, or continuation 
rates, while fewer publications assessed adherence based on 
proportion of days covered or medication-possession ratio. 
The results suggested better compliance with biological 
therapy in SpA compared to RA. Age, female sex, comorbidity, 
Table 4 Characteristics of adherence/persistence-related observational studies reviewed
Objective Demographic and clinical characteristics Main results
López-González 
et al39 (Spain)
To analyze evidence on 
adherence to BAs in RA, 
SpA, and PsA
A total of 24 publications were reviewed: 
19 included RA patients, nine SpA, and five 
chronic arthritis in general
Follow-up 1–9 years
Survival time of the BA was the most common 
measure of persistence (n=16); MPR or PDC 
the usual method to assess adherence (n=5)
Adherence to BAs was superior in SpA over RA.
Several factors were identified as adherence 
predictors. women were less adherent than men. 
A poor clinical condition at baseline was associated 
with lower persistence; however, high baseline 
CRP improved overall persistence. Methotrexate 
and other DMARDs increased adherence, but the 
number of previous DMARDs was associated with 
premature treatment discontinuation.
Lyu et al40 
(Germany)
To evaluate treatment 
persistence among RA, 
AS, and PsA patients 
initiating subcutaneous 
BAs in Germany
RA (n=576, 75% female, mean age 56.9 years, 
SD 13.1 years)
AS (n=108, 29.6% female, mean age 42 years, 
SD 11.5 years)
PsA (n=197, 50.3% female, mean age 
49.4 years, SD 10.6 years)
Persistence rates over 12 months were 51.9%, 
48.1%, and 57.9% for RA, AS, and PsA patients, 
respectively.
In AS and PsA, there was no significant difference 
in the time to discontinuation for naïve compared 
to experienced patients.
Saad et al41 
(UK)
To assess persistence 
with first-course and 
second-course treatment 
with BAs in PsA patients
PsA (n=566, 53% female, mean age 45.7 years, 
SD 11.1 years), disease duration 12.4 years, 
SD 8.7 years
At 12-month follow-up, 75.5% remained on their 
first BA, while 9.5% discontinued treatment due to 
inefficacy and 10% due to AEs.
Being female (HR 1.5, 95% Ci 1.0–1.7) and having 
baseline comorbidity (HR 1.5, 95% iC 1.1–2.0) 
were associated with significantly higher drug-
discontinuation rates.
Persistence with the second course of therapy was 
lower than with the first course.
Kristensen 
et al42 (Sweden)
To examine clinical 
characteristics as possible 
predictors of long-term 
treatment continuation 
with BAs in naïve AS 
patients
isolated AS (n=122, 25% female, mean age 
42 years, SD 12 years), disease duration 
15 years, SD 12 years
AS peripheral arthritis (n=121, 10% female, 
mean age 44 years, SD 12 years), disease 
duration 16 years, SD 12 years
Drug-survival rates at 12 and 24 months were 
86% and 78% for patients with peripheral arthritis 
and 74% and 68% for patients with isolated SA 
(P=0.05).
in both groups, at 24 months 11% of withdrawals 
were due to AEs and 13% due to inefficacy.
After 12 and 24 months, 93% and 85% of the 
patients with improvement in vAS global remained 
on treatment, while only 79% and 68% continued 
the treatment in the less favorable vAS global 
response (P,0.01), respectively.
Male sex (discontinuation HR 0.36, 95% Ci 
0.19–0.68) and presence of peripheral arthritis 
(HR 0.49, 95% Ci 0.27–0.88) were found to be 
statically significant predictors for continuation of 
therapy. This impact seemed to be mainly related to 
a lower risk of ceasing treatment due to inefficacy.
(Continued)
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Table 4 (Continued)
Objective Demographic and clinical characteristics Main results
wallman et al29 
(Sweden)
To compare clinical 
development, HRQoL 
and treatment adherence 
between nr-axSpA and 
AS patients during 3 years 
of BAs in clinical practice
nr-axSpA (n=86, 38% female, mean age 
38 years, SD 13 years), disease duration 
9 years, SD 9 years
AS (n=238, 24% female, mean age 43 years, 
SD 12 years), disease duration 16 years, 
SD 12 years
After 3 years of follow-up, the proportion of 
patients with nr-axSpA and AS remaining on BA 
therapy was 70% and 77%, respectively.
Male sex and higher brazilein CRP levels were 
significantly associated with better treatment 
persistence.
Favalli et al43 
(italy)
To evaluate the 8-year 
survival of first-BA 
patients with axSpA 
or PsA and identify 
predictive factors for 
withdrawal
PsA (n=298, 48.3% female, mean age 
47.8 years, SD 12.1 years), disease duration 
8.7 years, SD 7.7 years
axSpA (n=316, 30% female, mean age 
42.8 years, SD 12.1 years), disease duration 
7.2 years, SD 7.9 years
The cumulative 8-year retention rate was 51.9% in 
PsA patients and 57.2% in axSpA patients.
43.1% of patients with PsA and 42.1% with axSpA 
stopped the first-line BA. 22.4% of patients 
with PsA and 15.8% with axSpA reported that 
discontinuation was due to inefficacy, while 15% 
and 41.2% of patients, respectively, indicated that 
they stopped the treatment due to Aes.
Male sex (HR 0.595, 95% Ci 0.405–0.875; 
P=0.008) and concomitant methotrexate use were 
associated with a lower overall risk of withdrawal 
in PsA, but not in axSpA patients. High baseline 
BASDAi was a predictor of drug persistence in 
axSpA (HR 1.016, 95% Ci 1.002–1.030; P=0.028).
Hromadkova 
et al26 (Czech 
Republic)
To elucidate the 
relationship between drug 
compliance and HRQoL 
in patients with different 
rheumatic disorders
SpA (n=41, 68.1% female, mean age 50 (22–79) 
years), disease duration 3.8 (0.7–8.3) years
RA (n=178, 78.7% female, mean age 59  
(26–82) years), disease duration 7.4  
(0.5–19.9) years
SSc (n=41, 75.6% female, mean age 58 (26–80) 
years), disease duration 6.8 (0.5–23.9) years
JiA (n=23, 73.9% female, mean age 28 (18–51) 
years), disease duration 6.8 (0.6–20.9) years
Mean CQR score (0 nonadherence to 100 
complete adherence) in SpA patients was 77.1 
(42.1–97.9).
38.3% of patients with SpA were considered 
compliant (CQR ,80).
Patients with JiA were the least adherent 
(CQR 66), while patients with RA presented 
higher rates of adherence (CQR 82.5).
Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; BAs, biological agents; CQR, Compliance Questionnaire Rheumatology; HRQoL, health-related 
quality of life; JiA, juvenile idiopathic arthritis; MPR, medication-possession ratio; nr-axSpA, nonradiographic axial spondyloarthritis; PDC, proportion of days covered; 
PsA, psoriatic arthritis; SSc, systemic sclerosis.
poor clinical condition, and number of previous BAs were 
identified as explanatory factors for patient compliance.
Results of persistence in SpA patients were heterogeneous 
among the studies reviewed. Lyu et al40 observed that among 
AS and PsA patients who were initiating biological treatment, 
persistence at 12 months was relatively low (48%–58%). 
Nonetheless, Saad et al41 reported a higher survival rate on 
their index BA (75.5%) for patients with PsA after 12 months 
of follow-up. In line with these results, Kristensen et al42 
showed drug-survival rates at 12 and 24 months of 86% and 
78% for peripheral arthritis patients and 74% and 68% for 
patients with isolated AS starting biological therapy. Like-
wise, Wallman et al29 showed a high proportion of patients 
with nr-axSpA (70%) and AS (77%) remaining on BA 
therapy after three years follow up. For long-term persistence, 
Favalli et al43 reported cumulative 8-year retention of 57.2% 
for axSpA and 51.9% for PsA. Finally, related to compliance, 
Hromadkove et al26 reported that only 38.3% of patients 
with AS were compliant with BA treatment, as indicated by 
Compliance Questionnaire Rheumatology score ($80).
Satisfaction with decision making
Renzi et al44 examined PsA patients’ preferences about their 
role in the decision-making process, as well as their satis-
faction with both their care and their knowledge about PsA 
therapies (Table 5). Overall, the majority of PsA patients 
(72.7%) wanted to be involved in decision making, although 
40.6% preferred that their doctors make the final decision 
after considering their opinion; 65.5% of PsA patients 
reported being completely or fairly satisfied with their care 
and information. Multivariate analysis showed that informa-
tion on both treatment side effects and treatment options was 
significantly associated with overall satisfaction, confirming 
that improving patient–doctor communication may improve 
patients’ satisfaction with their care.
Patient preferences for SpA treatments
Two publications examined patient preferences for treatment 
characteristics (Table 5). Nolla et al45 assessed the rela-
tive importance given by patients with rheumatic diseases 
(RA, AS, and PsA) and rheumatologists to attributes of BAs. 
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Table 5 Characteristics of studies of satisfaction and preferences for treatment that were reviewed
Objective Demographic and clinical 
characteristics
Main results
Renzi et al44 
(italy)
To examine 
attitudes toward 
and satisfaction with 
decision making of 
patients with PsA 
compared with 
patients who had 
cutaneous psoriasis
PsA (n=33, 51% female, 61.5% 
aged #50 years, disease duration 
76.9% ,12 years)
Pso (n=207, 29.5% female, 64.7% 
aged #50 years, disease duration 
54.4% ,12 years)
Only 27.3% and 28.1% of patients with Pso and PsA preferred to 
leave decisions entirely to the doctor, whereas 72.7% and 71.9% 
wanted to be involved in decision making, respectively. No significant 
differences between groups were found.
Patients with PsA were more likely to be satisfied with the 
information they received about treatment side effects compared 
with patients with Pso (P,0.05).
Overall satisfaction of both groups was associated with the doctor 
asking the patient if they had preferences or concerns (P,0.001), 
the doctor considering the patient’s preferences (P,0.01), and the 
doctor informing the patient about treatment options (P,0.05) and 
potential side effects (P,0.01).
information about treatment and side effects (OR 5.11, 95% Ci 
2.5–15.0; P,0.001) and treatment options (OR 3.15, 95% Ci 1.4–7.1; 
P,0.01) were significantly associated with overall satisfaction.
The likelihood of preferring an active role increased with the patient’s 
level of knowledge of treatment (OR 5.67, 95% Ci 1.3–25.2; P,0.05) 
and the duration of disease (OR 2.03, 95% Ci 1.0–4.2; P,0.05).
Nolla et al45 
(Spain)
To define 
importance of 
values assigned to 
attributes of BAs by 
Spanish patients with 
rheumatic diseases 
(RA, AS, and PsA) 
and rheumatologists
AS (n=158, 28.2% female, mean 
age 46.3 [SD 11.4] years, disease 
duration 13.1 [SD 9.2] years)
PsA (n=165, 44.2% female, mean 
age 49.5 [SD 11.4] years, disease 
duration 12.6 [SD 8.2] years)
RA (n=165, 73.8% female, mean 
age 55.9 [SD 11.5] years, disease 
duration 13 [SD 7.8] years)
Treatment: 100% of study 
participants were currently being 
treated with BAs, 34% had received 
previous treatment with BAs
independently of the diagnosis, patients placed more importance on 
pain relief and improvement in functional capacity (Ri AS 37.8%, Ri 
PsA 41.6%, Ri AR 37.5%), followed by the risk of Aes (Ri AS 39%, Ri 
PsA%, Ri AR%), administration methods (Ri AS 25.7%, Ri PsA 24.6%, 
Ri AR 24.3%), and duration of effect (time until perceiving the need 
for a new dose) (Ri AS 17.1%, Ri PsA 15%, Ri AR 17.2%).
Rothery 
et al46 (UK)
To assess patients’ 
preferences for 
treatment-related 
benefits and risk of 
disease relapse in 
the management 
of patients in low 
disease states of PsA 
PsA (n=136, 46.6% female, 56.3% 
aged $55 years, 57% ,9 years’ 
disease duration)
Treatment 31.2% methotrexate 
alone, 15.4% other cDMARDs 
alone, 12.2% BAs alone, 27.5% 
methotrexate combined with 
cDMARDs or BAs, 3.2% other 
cDMARDs combined with 
BA,10.5% no medication
The most important benefit attribute was the elimination of severe 
side effects of sickness and nausea (weights 1.8668 and 0.7996, 
respectively).
Patients were willing to accept a very large increase in risk of 
relapse in exchange for improvements in levels of sickness/nausea 
(76.1% severe to some sickness/nausea, 32.6% some to no sickness/
nausea) and health status (30.1% health state 3 [no problems with 
mobility or self-care, some problems with performing usual activities, 
moderate pain or discomfort, and moderate anxiety or depression] 
to 2 [no problems with mobility, self-care, anxiety, or depression, 
some problems with performing usual activities, moderate pain or 
discomfort], 38.6% health state 1 [no problems with mobility or self-
care, usual activities, pain or discomfort, anxiety or depression] to 3).
Abbreviations: Ae, adverse event; AS, ankylosing spondylitis; BAs, biological agents; cDMARDs, conventional disease-modifying antirheumatic drugs; HRQoL, health-related 
quality of life; PsA, psoriatic arthritis; Pso, psoriasis; Ri, relative importance; SpA, spondyloarthritis.
For these patients, although efficacy (pain relief and 
improvement in functional capacity) and safety (risk of 
adverse events) were key aspects, both the frequency (time 
until perceiving the need for a new dose) and method of 
administration played an important role as attributes of 
BAs. Rothery et al46 observed that PsA patients conferred 
the greatest importance to eliminating severe side effects of 
sickness/nausea and the least importance to a change in risk 
of relapse. Patients were willing to accept a large increase 
in the risk of relapse in order to reduce the side effects of 
sickness/nausea.
Discussion
This review reports current knowledge on PROs in SpA 
patients in the EU. To date, the evidence indicates that similar 
to other rheumatic conditions,47 SpA patients report poorer 
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HRQoL compared to the general population. For AS patients, 
physical domains were more impaired than emotional well-
being, whereas for PsA patients both physical and psycho-
logical factors were strongly affected by the disease. Indeed, 
prevalence of depressive symptoms was higher in PsA than 
in AS and particularly high in patients with polyarthritis. In 
PsA, anxiety symptoms and concern about somatic symptoms 
were independently correlated with HRQoL, while in AS 
patients only impairment of cognitive function was found 
to be associated with HRQoL deterioration.
Work disability is a major problem for SpA patients. 
Indeed, these diseases tend to occur in the working-age popu-
lation, and studies have suggested that the ability to work and 
to perform ADL positively influence patients’ perceptions 
of their physical performance. In a cross-sectional study 
conducted in the US,7 limitations in ADL were significantly 
associated with lower PCS scores in patients with AS whereas 
for PsA patients ADL limitations were associated with both 
lower PCS and MCS scores, which supports results from EU 
reports in this review.
The PCS in AS patients is important. In these patients, 
physical restrictions in joint mobility, particularly of the 
spine,48,49 in addition to reductions in aerobic capacity50,51 and 
loss of skeletal muscle,52,53 are frequent. We found that physical 
function measured by the BASFI was highly correlated with 
HRQoL, indicating that functional impairment associated with 
AS can cause a significant impact on patients’ HRQoL, with 
important limitations on their daily activities. Conversely, 
PsA is a heterogeneous disease that is greatly influenced by 
psychological and social aspects of the disease. The most 
affected aspects of HRQoL in PsA patients were coping with 
a chronic disease, limitations on work and/or leisure time, 
and anxiety or depression. Interestingly, joint symptoms had 
a greater effect on PsA patients’ lives than skin symptoms.
Overall, SpA treatment has changed dramatically with 
the development of BAs.11–13 Substantial improvements in 
the signs and symptoms of PsA patients have been reported 
for these agents, although all BAs are similar in terms of 
efficacy and safety.54 The current evidence suggests that 
routine clinical use of BAs contributes greatly to the improve-
ment of HRQoL in SpA patients. Significantly, the greatest 
improvements were found in the PCS, with smaller but still 
significant improvements in the MCS.
However, the potential clinical benefits demonstrated 
by BAs in clinical trials may be reduced by poor adherence 
and early discontinuation of treatment in clinical practice, 
thereby increasing medical costs and resulting in the need 
for more aggressive treatments.55–57 Results on compliance 
with biological treatment of SpA patients were heterogeneous 
in real-life situations; nonetheless, all rates of persistence at 
12 months were .50% of the population, with no significant 
differences between PsA and AS patients and irrespective 
of the individual BA administered. A recent retrospective 
cohort study58 conducted in 53,477 BA-naïve patients with 
rheumatic conditions in the US reported that the majority of 
patients remained persistent in the first year of BA therapy; 
however, they observed lower adherence ratios when 
12-month medication-possession ratios were measured. 
Overall, in line with our results, patient characteristics, such 
as male sex, high disease activity, or peripheral arthritis, and 
treatment characteristics, such as concomitant methotrexate 
use, positively influence treatment persistence. Interestingly, 
higher HRQoL and a lower rate of functional disability were 
associated with lower compliance with treatment. According 
to Calip et al,58 young adults were less likely to be treatment-
compliant, resulting in more comorbidities, hospitalizations, 
or visits to the emergency department.
In rheumatic diseases, assessing and including patient 
preferences in the decision-making process have been found 
to contribute to increased medication adherence, improved 
treatment outcomes, reduced health care costs, and enhanced 
patient satisfaction.59–61 The available evidence suggests that 
European SpA patients attach great importance to outcomes 
(pain relief and improvement of functional capacity, low risk 
of adverse events); however, process attributes, such as self-
administration at home or longer time between doses, were 
also considered important attributes for BAs. Preferences 
varied depending on the PsA-disease states: low-disease-
state patients were more concerned about the side effects of 
sickness/nausea than about the risk of relapse.
Results on PsA patients confirm that most patients want to 
be involved in decision making about their treatment. Satis-
faction was associated with doctors providing treatment infor-
mation and actively involving patients in decision making. In 
line with these results, Nota et al62 reported that most patients 
with rheumatic disease preferred to be involved in decisions 
about their medication and especially preferred more par-
ticipation in decision making regarding their first treatment, 
which most commonly occurs in newly diagnosed patients.
Limitations
Possible limitations of this review include the heterogeneity 
of the articles retrieved in terms of patients, treatments, or 
methodology. Regarding the design, all studies assessing 
HRQoL in SpA were cross-sectional, and it is important 
to take into account that cross-sectional design might limit 
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comparisons among SpA patients and with other diseases 
and does not allow the drawing of final conclusions about 
the factors associated with HRQoL and their cause–effect 
relationship. On the other hand, there may be relevant 
publications in languages other than English and Spanish or 
that are indexed in different databases than those searched 
that we have not identified in this review.
Conclusion
SpA has a negative impact on patients’ HRQoL. The physical 
aspects of HRQoL, especially functioning limitations and 
pain, are severely affected in both AS and PsA patients. 
In PsA patients, the impact of disease on emotional well-being 
is considerable. In both disease, BA therapy is associated 
with improvements in both physical and emotional status. 
However, these potential improvements may be reduced by 
poor adherence. Even though there are inconsistent find-
ings, persistence rates in SpA patients are .50%, irrespec-
tive of the individual BA administered. Finally, results on 
preferences showed that most SpA patients preferred to be 
involved in decisions regarding their treatment, and although 
efficacy and safety are both considered essential, frequency 
and methods of administration also play a role as preference 
attributes for BA. These findings suggest that implementing 
management programs for SpA patients focused on the 
physical, emotional, and social consequences of the disease, 
in addition to assessing and including patient’s preferences 
in the treatment decision-making process, could be crucial in 
improving patients’ HRQoL and ensuring their satisfaction 
and compliance with treatment.
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